Skip to main content
. 2010 Feb;5(2):220–226. doi: 10.2215/CJN.06070809

Table 2.

Treatment parameters and intermediate outcomes for patients who were treated by INHD and matched control subjects who were on CHD as of January 1, 2007 (includes mean of last recorded values obtained from the previous month)

Parameter In-Center Long-Term Hemodialysis
INHD CHD
Treatment information
    time (min; mean ± SD) 470 ± 29 222 ± 28
    BFR (ml/min; mean ± SD) 306 ± 58 414 ± 57
    DFR (ml/min; mean ± SD) 496 ± 118 682 ± 129
    dialyzer surface area (%)
        1.5 m2 72.8 44.0
        1.8 m2 24.9 47.9
        2.0 m2 2.1 7.5
    other dialyzers 0.2 0.6
SF-36 quality-of-life scores (mean ± SD)a
    PCS 37.5 ± 11.7 33.1 ± 10.6
    MCS 49.0 ± 10.6b 47.9 ± 11.2
Laboratory variables (mean ± SD)
    eKt/V 2.21 ± 0.56 1.46 ± 0.32
    hemoglobin (g/dl) 12.16 ± 1.43b 12.11 ± 1.40
    albumin (g/dl) 3.95 ± 0.36 3.81 ± 0.42
    phosphorus (mg/dl) 5.31 ± 1.54c 5.50 ± 1.64
    TSat (%) 25.4 ± 9.9 27.2 ± 11.2
Interdialytic weight gain (kg; mean ± SD) 4.0 ± 1.5 2.8 ± 1.2
Interdialytic weight gain (% of weight; mean ± SD) 4.4 ± 1.6 3.7 ± 1.4
UF volume (L; mean ± SD) 4.0 ± 1.4 2.5 ± 1.1
UF rate (ml/h per kg; mean ± SD) 6.0 ± 2.0 8.8 ± 2.9
Predialysis SBP (mmHg; mean ± SD) 147.7 ± 21.1d 149.9 ± 21.5
Postdialysis SBP (mmHg; mean ± SD) 130.4 ± 19.4 135.3 ± 18.9
a

Only one in five patients with SF-36 scores in both groups (20.5% for INHD and 23.4% for CHD).

b

P = 0.3,

c

P = 0.003,

d

P = 0.009 versus CHD (all others at P < 0.0001).